BREAKING NEWS
This content is not available in your region

Roche wins Japan approval for personalised cancer drug Rozlytrek

Access to the comments Comments
Roche wins Japan approval for personalised cancer drug Rozlytrek
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann   -   Copyright  Arnd Wiegmann(Reuters)
Text size Aa Aa

ZURICH (Reuters) – Swiss drugmaker Roche on Tuesday won approval in Japan for Rozlytrek as the world’s biggest maker of cancer drugs pushes ahead in personalised medicines that require a biomarker test to identify prospective patients.

Roche said Japan is the first country to approve Rozlytrek, also known as entrectinib, targeting people with NTRK fusion-positive solid tumours, across 10 different tumour types, including those with central nervous system metastases.

(Reporting by John Miller; Editing by Michelle Martin)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.